Work

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Year: 2021

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2021-144706

Authors: Steven P. Treon, Christian Buske, Sheeba K Thomas, Jorge J. Castillo, Andrew R. Branagan, Meletios A. Dimopoulos, Maria Gavriatopoulou, Diego Cadavid, Felix T Garzon, Weihua Tang, Sean Seyffert, Varun Garg, Shariq Ali, Arthur G. Taveras, Kelly Chen, Jeffrey V. Matous

Institutions: Harvard University, Dana-Farber Cancer Institute, The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital, National and Kapodistrian University of Athens, X4 Pharmaceuticals, Inc. (United States), Colorado Blood Cancer Institute

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4200248924

Cites:

Cited by: 13

Related to: 10